المصدر: Stelrova-Foucher E, Colombet M, Rs LAG, Moreno F, Dolya A, Bray F, Hesselg P, Sh HY, Stler CA; CC-3 contrutors. ternatnal cence of chdhood cancer, 2001-10: a populatn-based regtry study. Lancet Oncol. 2017 Jun;18(6):719-731. do 10.1016/S1470-2045(17)30186-9. Epub 2017 Apr 11. Erratum : Lancet Oncol. 2017 Jun;18(6):e301.
Lam CG, Howard SC, Bouffet E, Prchard-Jones K. Scnce and health for all chdren wh cancer. Scnce. 2019 Mar 15;363(6432):1182-1186. do 10.1126/scnce.aaw4892.
Gohar SF, Como M, Pre J, Marchese V. Feasy and parent satfactn of a physal therapy terventn program for chdren wh acute lymphoblast leukem the fst 6 months of medal treatment. Pedtr Blood Cancer. 2011 May;56(5):799-804. do 10.1002/pbc.22713. Epub 2011 Jan 16.
VarnJW, Se M, Kurt PS. PedsQL 4.0: relby and valy of the Pedtr Qualy of Le ventory versn 4.0 gener core scales healthy and patnt populatns. Med Care. 2001 Aug;39(8):800-12. do 10.1097/00005650-200108000-00006.
VarnJW, Katz ER, Se M, Qugs DJ, Frdman-Bender A, Castro CM. The Pedtr Cancer Qualy of Le ventory (PCQL). strument development, descrte statts, and cross-formant varnce. J Behav Med. 1998 Apr;21(2):179-204. do 10.1023/a:1018779908502.
VarnJW, Burwkle TM, Katz ER, Meeske K, Dkson P. The PedsQL pedtr cancer: relby and valy of the Pedtr Qualy of Le ventory Gener Core Scales, Multensnal Fatue Scale, and Cancer Module. Cancer. 2002 Apr 1;94(7):2090-106. do 10.1002/cncr.10428.
Joffe L, Ladas EJ. Nutrn durg chdhood cancer treatment: current understandg and a path for future research. Lancet Chd Adolesc Health. 2020 Jun;4(6):465-475. do 10.1016/S2352-4642(19)30407-9. Epub 2020 Feb 13.
Orgel E, Genkger JM, Aggarwal D, Sung L, Nder M, Ladas EJ. Assoctn of body mass dex and surval pedtr leukem: a meta-analys. Am J Cl Nutr. 2016 Mar;103(3):808-17. do 10.3945/ajcn.115.124586. Epub 2016 Feb 10.
Rgwald-Smh K, Hl R, Evanoff L, Mart J, Sacks N. When Realy and Research Colle: Gueles Are Essentl for Optal Nutrn Care Pedtr Oncology. J Pedtr Hematol Oncol. 2022 Jan 1;44(1):e144-e151. do 10.1097/MPH.0000000000002200.
FabozzF, Trovato CM, DmantA, MastronuzzA, Zecca M, TrodS MasettR, LeardD, Muratore E, Barat V, Lezo A, De Lorenzo F, Cacclanza R, PedrazzolP. Management of Nutrnal Needs Pedtr Oncology: A Consensus Statement. Cancers (Basel). 2022 Jul 11;14(14):3378. do 10.3390/cancers14143378.
Tachana H, Koga K, Fujura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Bl. 2004 Apr;11(4):380-1. do 10.1038/nsmb743. Epub 2004 Mar 14.
Garc-Perdomo HA, Gomez-Ospa JC, Re LO. munonutrn hope? Oral nutrnal supplement on cancer treatment. t J Cl Pract. 2021 Nov;75(11):e14625. do 10.1111/cp.14625. Epub 2021 Jul 19.
PalagyA, Balane C, Shanthosh J, Jun M, Bhoo-Pathy N, Gadsden T, Canfell K, Jan S. Treatment abandonment chdren wh cancer: Does a sex dference ext? A systemat revw and meta-analys of evence from low- and mdle-come countrs. t J Cancer. 2021 Feb 15;148(4):895-904. do 10.1002/c.33279. Epub 2020 Sep 22.
Frdrh P, Lam CG, rgo E, Perez R, Reo RC, Arora RS. Magnude of Treatment Abandonment Chdhood Cancer. PLoS One. 2015 Sep 30;10(9):e0135230. do 10.1371/journal.pone.0135230. eCollectn 2015.
Gomez EV, Perez YM, Sanchez HV, Forment GR, Soler EA, Bertot LC, Garc AY, del Rosar Abreu Vazquez M, Fabn LG. Antxant and munomodulatory effects of Vs patnts wh chron hepat C. World J Gastroenterol. 2010 Jun 7;16(21):2638-47. do 10.3748/wjg.v16.1.2638.
Var Gomez E, Gra Oramas B, Soler E, Llan Navarro R, Ruenes Domech C. Vs, a nutrnal supplement, combatn wh terferon alpha-2b and rav patnts wh chron hepat C. Ler t. 2007 Mar;27(2):247-59. do 10.1111/j.1478-3231.2006.01411.x.
Hernandez-Garc S, Gonzalez V, Sanz E, Pandlla A. Effect of Oncox Oral Solutn HER2-Overexpressg Breast Cancer. Nutr Cancer. 2015;67(7):1159-69. do 10.1080/01635581.2015.1068819. Epub 2015 Aug 4.
Dz-Rodruez E, Hernandez-Garc S, Sanz E, Pandlla A. Antumoral effect of Ocox on acute myelo leukem. Oncotarget. 2016 Feb 2;7(5):6231-42. do 10.18632/oncotarget.6862.
Hernandez-Unzueta Benedto A, Olaso E, Sanz E, Vra C, Arteta B, Marquez J. Ocox oral solutn(R) as a complement to otecan chemotherapy the metastat progressn of colorectal cancer to the ler. Oncol Lett. 2017 Jun;13(6):4002-4012. do 10.3892/ol.2017.6016. Epub 2017 Apr 10.
A teacupful of mede? Nat Struct Mol Bl. 2008 Jun;15(6):537. do 10.1038/nsmb0608-537.
Sdu, As M, Hafeez BB, AdhamVM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor functn prostate cancer. FASEB J. 2011 Apr;25(4):1198-207. do 10.1096/fj.10-167924. Epub 2010 Dec 21.
Mlan SA, Burke P, Coleman DT, Below RL, Steffan JJ, Carroll JL, Wlms BJ, CardellJA. The green tea polyphenol EGCG potenttes the antrolerate acty of c-Met and epermal growth factor receptor hors non-small cell lung cancer cells. Cl Cancer Res. 2009 Aug 1;15(15):4885-94. do 10.1158/1078-0432.CCR-09-0109. Epub 2009 Jul 28.
Yang C, Du W, Yang D. hn of green tea polyphenol EGCG((-)-epallocatech-3-gallate) on the proleratn of gastr cancer cells by suppressg canonal wnt/beta-caten snallg pathway. t J Food ScNutr. 2016 Nov;67(7):818-27. do 10.1080/09637486.2016.1198892. Epub 2016 Jun 24.
Maruyama T, Murata S, Nakayama K, Sano N, Ogawa K, NowatarT, Tamura T, NozakR, Fukunaga K, OhkohchN. (-)-Epallocatech-3-gallate suppresses ler metastas of human colorectal cancer. Oncol Rep. 2014 Feb;31(2):625-33. do 10.3892/or.2013.2925. Epub 2013 Dec 13.
RoomMW, RoomN, anov V, Kalovsky T, NdzwckA, Rath M. hn of pulmonary metastas of melanoma b16fo cells C57BL/6 me by a nutrnt mture constg of ascorb Ac, lyse, prole, arge, and green tea extract. Exp Lung Res. 2006 Nov-Dec;32(10):517-30. do 10.1080/01902140601098552.
Exploratory Study to Evaluate the Effect and Safety of the Use of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06363201Test

المصدر: A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06362369Test

المصدر: A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06242470Test

المؤلفون: Cy Biopharma, Pancreatic Cancer North America

المساهمون: Yvan Beaussant, MD, MSci, Sponsor Investigator

المصدر: Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06001749Test

المصدر: A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants With Pathologically Confirmed Cancer Refractory to Conventional Therapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05990920Test

المصدر: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05891171Test

المصدر: Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05877430Test

المؤلفون: Regeneron Pharmaceuticals

المصدر: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05864144Test

المصدر: A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05714553Test

المصدر: Phase 1 Study to Evaluate the Safety, PK, PD, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects With Advanced Malignancies

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05584111Test